Endostatin, a fragment of collagen XVIII, is recognized for its anti-angiogenic properties, which makes it a target of interest for cancer therapies. Traditionally, its mechanism of action has been attributed to its ability to inhibit endothelial cell proliferation and migration. However, the latest findings suggest that its functionality extends beyond the cytoplasmic locale, facilitating its movement into the nucleus. This transition to the nucleus implies a deeper regulatory role by modifying gene expression directly involved in angiogenesis.

The study conducted by Song, Ding, Zhuo, and colleagues illustrates that the receptor nucleolin is the facilitator of this nuclear translocation. Nucleolin itself is associated with various cellular processes, including ribosome biogenesis, chromatin remodeling, and regulation of gene expression. Understanding the interplay between endostatin and nucleolin could significantly alter existing perspectives on angiogenesis regulation. The coupling of nucleolin’s receptor role with the anticancer properties of endostatin forms a novel research avenue with potential to unravel new cellular pathways exploited during tumor angiogenesis.

A particularly compelling aspect of their work highlights how this nuclear translocation affects signal transduction pathways that control endothelial cell function. When endostatin binds to nucleolin, it not only influences its localization within the cell but may also initiate a cascade of molecular events that could modify endothelial gene expression patterns. This discovery serves as a reminder that proteins such as endostatin hold not just local function but can integrate into larger cellular signaling networks, impacting cell fate and functionality.

Furthermore, this editorial encapsulates the essence of scientific vigilance, emphasizing the need for ongoing scrutiny of novel findings in the field. The concerns raised serve to alert the scientific community to revisit and replicate these findings before they become accepted mainstream knowledge. Concerns in scientific publications often stimulate productive discussion and reevaluation, ultimately strengthening the body’s collective understanding of complex biological processes.

Another key takeaway from the editorial is the importance of validated methodologies in exploring nuanced interactions within cellular environments. The claims regarding endostatin’s behavior were established through various experimental techniques, including immunoassays and confocal microscopy. These methodologies are crucial not just for confirming findings but also for ensuring that the data presented can withstand rigorous peer review and duplication efforts within the research community.

Angiogenesis, or the formation of new blood vessels from pre-existing ones, plays a fundamental role in both health and disease. At its core, it is essential for wound healing and tissue repair, yet it is also a hallmark of cancer progression, allowing tumors to grow and metastasize. Therefore, targeting the mechanisms that regulate angiogenesis, like the interaction between endostatin and nucleolin, could yield revolutionary advancements in the treatment of various cancers where angiogenesis is dysregulated.

As the research community continues to grapple with the complexities of cancer biology, findings such as those detailed in this editorial are crucial in deciphering how the cellular players interact. There exists a pressing need to develop therapies that can effectively disrupt these interactions, leading to targeted interventions that can curb tumor growth without affecting surrounding healthy tissues. The implications of understanding endostatin’s interaction with nucleolin extend far beyond basic science; they touch upon the realm of therapeutic intervention and public health.

Further research will undoubtedly be required to develop a comprehensive understanding of the downstream effects stemming from the nucleolin-mediated nuclear translocation of endostatin. Experimental validation in diverse cell lineages and pathological conditions will be necessary for extending these findings from model systems into potential clinical applications. It might also be exciting to explore whether other known angiogenesis inhibitors exhibit similar behaviors and receptor interactions.

Moreover, the potential for synergistic therapeutic strategies that combine endostatin with other modalities targeting nucleolin cannot be underestimated. Such approaches could maximize anti-tumor efficacy while minimizing side effects resulting from non-specific therapies. Given that many of the current cancer treatments grapple with issues of specificity and resistance, revisiting established molecules like endostatin offers an exciting path forward to enrich our arsenal against cancer.

In conclusion, the editorial expression of concern surrounding the nuclear translocation of endostatin, mediated by nucleolin, serves as an impetus for robust discussion and further investigation into its implications for cancer treatment strategies. The evolving landscape of our understanding of angiogenesis and its regulation will no doubt benefit from ongoing research efforts in this promising arena, heralding a new era where the intricacies of cell biology can lead to innovative therapies for the fight against cancer.

Thus, while concerns have been raised, they serve as a beneficial component in the continual pursuit of knowledge within the scientific community. As researchers remain vigilant, the promise of unlocking new therapeutic modalities tailored to fight cancer more effectively grows ever closer.

Subject of Research: The nuclear translocation of endostatin mediated by its receptor nucleolin in endothelial cells.

Article Title: Editorial Expression of Concern: The nuclear translocation of endostatin is mediated by its receptor nucleolin in endothelial cells.

Article References:

Song, N., Ding, Y., Zhuo, W. et al. Editorial Expression of Concern: The nuclear translocation of endostatin is mediated by its receptor nucleolin in endothelial cells.
Angiogenesis 28, 58 (2025). https://doi.org/10.1007/s10456-025-10014-8

Image Credits: AI Generated

DOI:

Keywords: Endostatin, nucleolin, angiogenesis, cancer therapy, nuclear translocation, endothelial cells, molecular interactions.

At the heart of the TME’s complexity lies the dual nature of ferroptosis: it is both a weapon against malignant cells and a modulator of immune function. Cytotoxic CD8⁺ T cells are now known to potentiate antitumor activity by releasing interferon-gamma (IFN-γ), which downregulates the system xc^– cystine/glutamate antiporter in cancer cells, thereby depleting glutathione (GSH)—a key antioxidant. This depletion sensitizes tumor cells to ferroptosis, revealing a novel immunological mechanism of tumor suppression. Moreover, IFN-γ influences the phenotype of tumor-associated macrophages (TAMs), driving their transformation toward the pro-inflammatory M1 subtype that supports tumor eradication and impedes cancer progression.

Conversely, immune cells themselves are not impervious to ferroptosis within the TME. CD8⁺ and CD4⁺ T cells exhibit lipid peroxidation under conditions of impaired glutathione peroxidase 4 (GPX4) activity or exposure to ferroptosis inducers like RSL3, resulting in compromised immune function. Strikingly, overexpression of protective proteins such as GPX4 and ferroptosis suppressor protein 1 (FSP1) shields these lymphocytes from ferroptotic death. These insights underscore the delicate balance wherein immune cells navigate oxidative stress—not merely as bystanders but as active participants whose survival directly impacts antitumor immunity.

Regulatory T cells (Tregs), notorious for suppressing immune responses, also intertwine with ferroptosis pathways. In the absence of GPX4, Tregs demonstrate heightened ferroptotic sensitivity, leading to the secretion of pro-inflammatory cytokines such as IL-1β, which paradoxically facilitates the expansion of tumor-promoting T helper 17 (Th17) cells. This phenomenon illustrates how ferroptosis modulation within Tregs could recalibrate the immunosuppressive landscape of the TME; however, the therapeutic challenge remains to selectively target tumor-infiltrating Tregs without unleashing systemic autoimmunity.

B cells, especially the marginal zone and B1 subsets, have recently been implicated in ferroptotic regulation within tumors. These cells’ reliance on fatty acid uptake through scavenger receptors like CD36 predisposes them to lipid peroxide accumulation and ferroptosis when GPX4 activity wanes. The metabolic reprogramming intrinsic to their survival and function adds a further layer of complexity, suggesting that ferroptosis not only shapes lymphocyte fate but also influences humoral responses in cancer contexts.

Dendritic cells (DCs), vital for antigen presentation and T cell activation, are vulnerable to ferroptotic damage wrought by oxidative stress and lipid peroxidation by-products. This accumulation triggers endoplasmic reticulum stress and engages transcriptional programs such as the X-box binding protein 1 (XBP1) pathway, undermining DCs’ immunostimulatory capacity. Intriguingly, ferroptosis in DCs can be mitigated by blocking peroxisome proliferator-activated receptor gamma (PPARγ), opening avenues to preserve their tumor-fighting potential in the oxidative TME milieu.

Macrophages within tumors exhibit a fascinating interplay between polarization states and ferroptosis susceptibility. While immunosuppressive M2 macrophages display sensitivity to ferroptosis inducers, the classically activated M1 subset resists ferroptosis via inducible nitric oxide synthase (iNOS)-mediated nitric oxide production that counteracts lipid peroxide formation. Inducing ferroptosis in TAMs can reprogram M2 macrophages into M1-like phenotypes, facilitating antitumoral immunity and providing a promising therapeutic strategy. Emerging nanoparticle-based ferroptosis inducers have demonstrated capacity to harness this phenotype switch, igniting robust phagocytic activity and inhibiting metastatic dissemination.

Natural killer (NK) cells, crucial innate effectors, face ferroptotic threats primarily through lipid peroxidation triggered by tumor metabolites like L-Kynurenine. This lipid oxidative stress impairs NK cell glycolysis—a metabolic pathway essential for their cytotoxic function. Protective factors such as GPX4 overexpression and nuclear factor erythroid 2–related factor 2 (NRF2) activation can rescue NK cells from ferroptosis and restore their antitumor efficacy. These mechanistic insights provide a foundation for enhancing NK cell resilience in hostile tumor niches.

Myeloid-derived suppressor cells (MDSCs), particularly polymorphonuclear subsets, undergo spontaneous ferroptosis in the TME due to heightened oxidative stress and GPX4 downregulation. While ferroptosis reduces MDSC numbers, the release of immunosuppressive lipid mediators like prostaglandin E2 (PGE2) following cell death paradoxically hinders antitumor T cell activity and supports TAM-mediated immune evasion. Thus, ferroptosis in MDSCs presents a double-edged sword, demanding nuanced therapeutic interventions that consider downstream immunomodulatory effects.

Cancer-associated fibroblasts (CAFs) contribute substantially to tumor resistance against ferroptosis by supplying antioxidant molecules such as GSH and cysteine. This metabolic support disrupts ferroptotic cascades in cancer cells, shielding tumors from cell death. Notably, CD8⁺ T cell-derived IFN-γ counteracts CAF-mediated protection by inducing γ-glutamyltransferase 5 (GGT5) expression, which degrades extracellular GSH and curtails antioxidant availability. Concurrently, IFN-γ suppresses the tumor’s system xc^– expression via JAK/STAT signaling, intensifying tumor vulnerability to ferroptosis. This interplay exemplifies the tug-of-war between cancer cells, stromal components, and immune effectors within the ferroptotic landscape.

Collectively, the dynamic interactions between ferroptosis and the multifarious cell types within the TME underscore an intricate regulatory network with profound implications for cancer biology. Therapeutic approaches leveraging ferroptosis must, therefore, consider impacts not only on tumor cells but also on immune and stromal compartments that critically modulate antitumor immunity. Targeted induction of ferroptosis in tumor cells combined with preservation or restoration of immune cell function holds promise for next-generation cancer therapies.

The emerging paradigm situates ferroptosis as a nexus connecting metabolic reprogramming, oxidative stress, and immune regulation. Beyond its cytotoxic role, ferroptosis shapes the immunological milieu, influencing antigen presentation, immune cell polarization, and cytokine milieu, thereby dictating either tumor suppression or progression. Enhancing our mechanistic understanding will facilitate the design of precision interventions that harness ferroptosis within the immune contexture of tumors.

Future research priorities include developing selective ferroptosis modulators capable of discriminating between pro-tumorigenic and anti-tumorigenic cell populations, optimizing delivery systems such as ferroptosis-inducing nanoparticles, and integrating ferroptosis-targeted therapies with immune checkpoint blockade. Additionally, deeper insights into metabolic dependencies that predispose immune subsets to ferroptotic death will enable strategies to bolster immune resilience amidst TME oxidative challenges.

In sum, ferroptosis transcends its traditional role as a form of cell death to emerge as a pivotal orchestrator within the tumor-immune ecosystem. Its dualistic nature—as a facilitator of tumor cell demise and a determinant of immune cell viability—presents both opportunities and obstacles in the quest to reprogram the TME toward tumor eradication. As our knowledge base expands, ferroptosis promises to unlock novel frontiers in oncology, heralding transformative advances in immunometabolic cancer therapy.

Subject of Research:
Ferroptosis and its complex role within the tumor microenvironment, focusing on interactions between immune cells and cancer cells in esophageal cancer.

Article Title:
Exploring the role of ferroptosis in esophageal cancer: mechanisms and therapeutic implications.

Article References:
Zhao, D., Li, W., Han, Z. et al. Exploring the role of ferroptosis in esophageal cancer: mechanisms and therapeutic implications. Cell Death Discov. 11, 405 (2025). https://doi.org/10.1038/s41420-025-02696-2

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-025-02696-2